WO1997004765A1 - INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE - Google Patents
INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE Download PDFInfo
- Publication number
- WO1997004765A1 WO1997004765A1 PCT/US1996/012257 US9612257W WO9704765A1 WO 1997004765 A1 WO1997004765 A1 WO 1997004765A1 US 9612257 W US9612257 W US 9612257W WO 9704765 A1 WO9704765 A1 WO 9704765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coa
- inhibitor
- cells
- mammal
- trifluoromethyl
- Prior art date
Links
- 108010011435 arachidonyl transacylase Proteins 0.000 title claims abstract description 19
- 230000006907 apoptotic process Effects 0.000 title claims description 30
- 230000005764 inhibitory process Effects 0.000 title description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 52
- 241000124008 Mammalia Species 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 230000004663 cell proliferation Effects 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 230000001603 reducing effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 41
- 229960005536 Alkyl-lysophospholipid Drugs 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 2
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- 150000001875 compounds Chemical class 0.000 description 62
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 229940114078 arachidonate Drugs 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ROEBFCUWXFBXJZ-UHFFFAOYSA-N 1-(7-diethoxyphosphorylheptyl)-3,4,5-triphenylimidazol-2-one Chemical compound C=1C=CC=CC=1N1C(=O)N(CCCCCCCP(=O)(OCC)OCC)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ROEBFCUWXFBXJZ-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 13
- HZCUOEVEYNOQRW-UHFFFAOYSA-N 4,5-dichloro-2-[2-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-4-(trifluoromethyl)phenoxy]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(Cl)=C(Cl)C=C1OC1=CC=C(C(F)(F)F)C=C1NC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 HZCUOEVEYNOQRW-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- -1 Lipids Lipid Chemical class 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 210000001589 microsome Anatomy 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102100026918 Phospholipase A2 Human genes 0.000 description 4
- 108010003541 Platelet Activating Factor Proteins 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 150000003863 ammonium salts Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 4
- QILSFLSDHQAZET-UHFFFAOYSA-N diphenylmethanol Chemical compound C=1C=CC=CC=1C(O)C1=CC=CC=C1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- VWKSVPJJPNTCFZ-UHFFFAOYSA-N 2-[2-[[3,5-bis(trifluoromethyl)phenyl]sulfonylamino]-4-(trifluoromethyl)phenoxy]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1NS(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VWKSVPJJPNTCFZ-UHFFFAOYSA-N 0.000 description 3
- CBHLOURCTLPFMR-UHFFFAOYSA-N 2-[2-amino-4-(trifluoromethyl)phenoxy]benzoic acid Chemical compound NC1=CC(C(F)(F)F)=CC=C1OC1=CC=CC=C1C(O)=O CBHLOURCTLPFMR-UHFFFAOYSA-N 0.000 description 3
- VPVCXCYVVCRXNG-UHFFFAOYSA-N 5-(2-oxo-3,4,5-triphenylimidazol-1-yl)pentanoic acid Chemical compound C=1C=CC=CC=1N1C(=O)N(CCCCC(=O)O)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VPVCXCYVVCRXNG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 108010058864 Phospholipases A2 Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NLMKTWRXQNCJKC-UHFFFAOYSA-N 1-(3,4-dichlorophenoxy)-2-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(Cl)C(Cl)=C1 NLMKTWRXQNCJKC-UHFFFAOYSA-N 0.000 description 2
- TZGFQIXRVUHDLE-UHFFFAOYSA-N 1-chloro-2-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1Cl TZGFQIXRVUHDLE-UHFFFAOYSA-N 0.000 description 2
- NORYGGNDZGVBFY-UHFFFAOYSA-N 2-[2-amino-4-(trifluoromethyl)phenoxy]-4,5-dichlorobenzenesulfonic acid Chemical compound NC1=CC(C(F)(F)F)=CC=C1OC1=CC(Cl)=C(Cl)C=C1S(O)(=O)=O NORYGGNDZGVBFY-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SIOZTHVHTVAQIM-UHFFFAOYSA-N 4,5-dichloro-2-[2-nitro-4-(trifluoromethyl)phenoxy]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(Cl)=C(Cl)C=C1OC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O SIOZTHVHTVAQIM-UHFFFAOYSA-N 0.000 description 2
- YAAYYZWXXRULES-UHFFFAOYSA-N 4-(2-methylbutan-2-yl)-2-[2-nitro-4-(trifluoromethyl)phenoxy]benzenesulfonyl chloride Chemical compound CCC(C)(C)C1=CC=C(S(Cl)(=O)=O)C(OC=2C(=CC(=CC=2)C(F)(F)F)[N+]([O-])=O)=C1 YAAYYZWXXRULES-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 2
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- AIEAQDBEOIZCCK-UHFFFAOYSA-N ethyl 5-(1,4,5-triphenylimidazol-2-yl)oxypentanoate Chemical compound C=1C=CC=CC=1N1C(OCCCCC(=O)OCC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 AIEAQDBEOIZCCK-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- XQOSMFSVUSRKGV-UHFFFAOYSA-N methyl 2-[2-amino-4-(trifluoromethyl)phenoxy]benzoate Chemical compound COC(=O)C1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1N XQOSMFSVUSRKGV-UHFFFAOYSA-N 0.000 description 2
- FXGNOIURDFRTDL-UHFFFAOYSA-N methyl 2-[2-nitro-4-(trifluoromethyl)phenoxy]benzoate Chemical compound COC(=O)C1=CC=CC=C1OC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O FXGNOIURDFRTDL-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 2
- 229960005332 zileuton Drugs 0.000 description 2
- HTFCJBTVENNZSQ-UHFFFAOYSA-N 1,4,5-triphenylimidazole Chemical compound C=1C=CC=CC=1N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HTFCJBTVENNZSQ-UHFFFAOYSA-N 0.000 description 1
- PESPBNYBZVIGRO-UHFFFAOYSA-N 1-bromo-2-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1Br PESPBNYBZVIGRO-UHFFFAOYSA-N 0.000 description 1
- NBJZEUQTGLSUOB-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC=C1Cl NBJZEUQTGLSUOB-UHFFFAOYSA-N 0.000 description 1
- NRSSOFNMWSJECS-UHFFFAOYSA-N 1-isocyanato-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC(C(F)(F)F)=C1 NRSSOFNMWSJECS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BARNAHOWRVURRB-UHFFFAOYSA-N 2-(7-diethoxyphosphorylheptoxy)-1,4,5-triphenylimidazole Chemical compound C=1C=CC=CC=1N1C(OCCCCCCCP(=O)(OCC)OCC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BARNAHOWRVURRB-UHFFFAOYSA-N 0.000 description 1
- WRAJCSLJYQCOMO-UHFFFAOYSA-N 2-[2-amino-4-(trifluoromethyl)phenoxy]-4-(2-methylbutan-2-yl)benzenesulfonamide Chemical compound CCC(C)(C)C1=CC=C(S(N)(=O)=O)C(OC=2C(=CC(=CC=2)C(F)(F)F)N)=C1 WRAJCSLJYQCOMO-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- BTRCVKADYDVSLI-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(S(Cl)(=O)=O)=C1 BTRCVKADYDVSLI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PLWROONZUDKYKG-DOFZRALJSA-N AACOCF3 Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F PLWROONZUDKYKG-DOFZRALJSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101000597249 Bacillus cereus Phospholipase C Proteins 0.000 description 1
- 101000730491 Bacillus cereus Phospholipase C Proteins 0.000 description 1
- NEJUAPUUTVQQNN-GAWNQNAESA-N CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NEJUAPUUTVQQNN-GAWNQNAESA-N 0.000 description 1
- 241000276573 Cottidae Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710195384 Group IIC secretory phospholipase A2 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical compound O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000583281 Sugiura Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000008052 TBE buffer with ethidium bromide Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- HAHJDPSGHVEDCE-UHFFFAOYSA-N [N+](=O)([O-])C1=C(OC2=C(C=CC(=C2)C(CC)(C)C)S(=O)(=O)N)C=CC(=C1)C(F)(F)F.NC1=C(OC2=C(C=CC(=C2)C(CC)(C)C)S(=O)(=O)N)C=CC(=C1)C(F)(F)F Chemical compound [N+](=O)([O-])C1=C(OC2=C(C=CC(=C2)C(CC)(C)C)S(=O)(=O)N)C=CC(=C1)C(F)(F)F.NC1=C(OC2=C(C=CC(=C2)C(CC)(C)C)S(=O)(=O)N)C=CC(=C1)C(F)(F)F HAHJDPSGHVEDCE-UHFFFAOYSA-N 0.000 description 1
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- FZMPYOWLQQANBP-UHFFFAOYSA-N azanium;4-(2-methylbutan-2-yl)-2-[2-nitro-4-(trifluoromethyl)phenoxy]benzenesulfonate Chemical compound [NH4+].CCC(C)(C)C1=CC=C(S([O-])(=O)=O)C(OC=2C(=CC(=CC=2)C(F)(F)F)[N+]([O-])=O)=C1 FZMPYOWLQQANBP-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001236 detergent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002015 diradylglycerols Chemical class 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 1
- ZZPLHDDZCSZACK-UHFFFAOYSA-N ethyl 6-(1,4,5-triphenylimidazol-2-yl)oxyhexanoate Chemical compound C=1C=CC=CC=1N1C(OCCCCCC(=O)OCC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ZZPLHDDZCSZACK-UHFFFAOYSA-N 0.000 description 1
- DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- VAJFLSRDMGNZJY-UHFFFAOYSA-N heptylphosphonic acid Chemical compound CCCCCCCP(O)(O)=O VAJFLSRDMGNZJY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000010661 induction of programmed cell death Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention is to the discovery of a new method to treat cell proliferation and cancer in an animal.
- ET- 18-O-CH3 has shown some efficacy in the treatment of patients suffering from leukemias and carcinomas (Berdel et al, Cancer 50: 2011-2015 (1982); Andreesen et al, J. Natl. Can. Inst. 70: 623-627 (1983); Andreesen, Prog. Biochem. Pharmacol. 22: 118-131 (1988)).
- Coenzyme A-independent transacylase is an enzyme responsible for the movement of arachidonate between phospholipid molecular species of inflammatory cells. CoA-IT removes arachidonate from the sn-2 position of 1-acyl-containing phosphoiipids, such as l-acyl-2-arachidonoyl-.m-glycero-3-phosphocholine (l-acyl-2- arachidonoyl-GPC).
- lyso-phospholipid acceptor such as l-alkyl-2-lyso-GPC and l-alkenyl-2-lyso-5 «-glycero-3-phospho- ethanolamine
- a suitable lyso-phospholipid acceptor such as l-alkyl-2-lyso-GPC and l-alkenyl-2-lyso-5 «-glycero-3-phospho- ethanolamine
- This activity is selective for 20 carbon fatty acyl groups and is the mechanism by which inflammatory cells move arachidonate into specific phospholipid pools prior to its release (Winkler and Chilton, Drug News Perspec. 6: 133-138 (1993); Snyder et al, J. Lipid Mediat. 10: 25-31 (1994)).
- the present invention is a method to decreasing, inhibiting or reducing cell proliferation in a mammal, and inducing apoptosis in a mammal, preferably in a human, by inhibition of the enzyme CoA-IT.
- This effect, induced by inhibition of CoA-IT can be accomplished by structurally distinct classes of compounds. Therefore the present invention is to the use of CoA-IT inhibitors for the treatment of cell proliferation, in mammals, preferably humans, in need of such treatment, by administering to said human an effective amount of a CoA-IT inhibitory compound, or pharmaceutically acceptable salt thereof.
- a preferred disease state, for treatment herein, associated with cell proliferation is psoriasis, rheumatoid arthritis or atherosclerosis.
- Another aspect of the present invention is to a method of treating a cancerous cell growth in a mammal, preferably a human, in need of such treatment, which method comprises administering to said mammal an effective amount of a CoA-independent transacylase (CoA-IT) inhibitor, or pharmaceutically acceptable salt thereof; provided that the inhibitor is not l-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (ET-18- O-CH3) or an alkyl lysophospholipid analog.
- the CoA-IT inhibitor may be co-administered with an effective amount of ET-I8-O-CH3 or an alkyl lysophospholipid analog.
- a preferred disease state, for treatment herein, associated with cancerous cell growth is leukemia.
- Another aspect of the present invention is to a method of inducing apoptosis in a mammal, in need of such treatment which method comprises administering to said human or mammal an effective amount of a CoA-independent transacylase (CoA-IT) inhibitor, or pharmaceutically acceptable salt thereof; provided that the inhibitor is not l-O- octadecyl-2-O-methyl-5rt-glycero-3-phosphocholine (ET-I8-O-CH3) or an alkyl lysophospholipid analog.
- the CoA-IT inhibitor may be co-administered with an effective amount of ET-I8-O-CH3 or an alkyl lysophospholipid analog.
- Figure 2 demonstrates the kinetics of ET-I8-O-CH3 inhibition of CoA-IT activity.
- U937 microsomes were incubate with the indicated concentrations of ET-I8-O-CH3 and l-alkyl-2-lyso-GPC as described in the Methods section herein. The quantities of product produced in the reactions were determined. A double-reciprocal plot of 1/velocity versus l/[product] is shown.
- Figure 3 demonstrates the effect of ET-I8-O-CH3 (A), diethyl 7-(3,4,5-triphenyl-2-oxo- 2,3-dihydro-imidazol-l-yl)heptane-phosphonate (B, Compound III) and 2-[2-[3-(4- Chloro-3-trifluoromethylphenyl) ureido] -4-trifluoromethyl phenoxy]-4,5- dichlorobenzene sulfonic acid (C, Compound I) on HL-60 cell proliferation.
- HL-60 cells were treated at time 0 with the indicated concentrations of compound and the number of viable cells determined by trypan blue exclusion after 24 and 48 hours.
- Figure 4 demonstrates the effect of ET-I8-O-CH3 on DNA synthesis in HL-60 cells.
- HL-60 cells were treated with various concentrations of compound or vehicle. Twenty- four hours prior to harvesting the cells, they were given a pulse of [ ⁇ Hlthymidine. At the indicated time points, the cells were harvested, washed, lysed and the amount of [ ⁇ H] incorporated into DNA was measured as described in the Methods. The results are the means + SD of triplicate determinations and are representative of 3 experiments.
- Figure 5 demonstrates the effects of ET-I8-O-CH3, 2-[2-[3-(4-Chloro-3- trifluoromethylphenyl)ureido]-4-trifluoromethyl phenoxy]-4,5-dichlorobenzene sulfonic acid (Compound I) and diethyl 7-(3,4,5-tripheny l-2-oxo-2,3-dihydro- imidazol- 1- yl)heptane-phosphonate (Compound III) on DNA fragmentation in HL-60 cells.
- HL-60 cells were treated with the indicated concentration of compound and DNA fragmentation determinate after 24 hours as described in the Methods. Control is vehicle treatment and the arrow indicates the internal standard fragment.
- Figure 6 demonstrates the effects of ET-I8-O-CH3, 2-[2-[3-(4-Chloro-3- trifluoromethylphenyl)ureido]-4-trifluoromethyl phenoxy]-4,5-dichlorobenzene sulfonic acid (Compound I) and diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-l- yl)heptane-phosphonate (Compound III) on the content of arachidonate in phosphatidylethanolamine subclasses of HL-60 cells.
- HL-60 cells were treated with ET- I8-O-CH3 (25 ⁇ M), Compound I (50 ⁇ M), Compound III (25 ⁇ M) or vehicle for 48 hours and A A content determined as described in the Methods.
- Figure 7 demonstrates the inco ⁇ oration of [3H]thymidine by chronic myelogenous leukemic cells following incubation with inhibitors for 20 hours. - o -
- CoA-IT represents a crucial event in the regulation of 'cancer' cell growth, and in particular apoptosis, Therefore, inhibition of CoA-IT will have a profound therapeutic effect on proliferative diseases and treatment of them thereby.
- ET-I8-O-CH3 was examined for its effect on CoA-IT activity in U937 microsomes by measuring the acylation of l-[-1H]alkyl-2-lyso-GPC to form product, [ 3 H]l-alkyl-2-arachidonoyl-GPC.
- the results ( Figure 1) showed that ET-I8-O-CH3 was a potent inhibitor of CoA-IT activity with an IC5 of 0.5 uM and complete inhibition observed at 3 uM.
- kinetic analysis experiments were performed. These data ( Figure 2) revealed that ET-18- O-CH3 inhibited CoA-IT activity in a manner that was best fit by a model of competitive competition.
- ET-I8-O-CH3 is a CoA-IT inhibitor, interacting with CoA-IT in a specific and predictable manner and that the inhibition of CoA-IT was not caused by a non-specific effect, such as a detergent effect on the microsomal membranes.
- ET-I8-O-CH3 has been shown to block the proliferation of cancer cells. Therefore, another aspect of the present invention is the discovery that ET- I8-O-CH3 is a potent inhibitor of the enzyme CoA-IT and hence is useful for treating a
- CoA-IT mediated disease or disorder in a mammal in need thereof comprises administering to said mammal an effective amount of l-O-octadecyl-2-O- methyl--?n-glycero-3-phosphocholine (ET-I8-O-CH3) as a CoA-IT inhibitor; provided that the disease or disorder is other than inhibiting cell proliferation or inducing apoptosis.
- E-I8-O-CH3 l-O-octadecyl-2-O- methyl--?n-glycero-3-phosphocholine
- ET-I8-O-CH3 is a potent inhibitor of CoA-IT raised the question of whether other structurally different CoA-IT inhibitors would influence proliferation in a manner comparable to ET-I8-O-CH3.
- Figure 3 illustrates the effects of ET-I8-O-CH3 and two distinct classes of compounds which are CoA-IT inhibitors on the proliferation of HL-60 cells.
- ET-I8-O-CH3 reduced the number of HL-60 cells in culture in a dose and time-dependent manner (Figure 3).
- two other structurally different CoA-IT inhibitors blocked the increases in cell numbers in a comparable fashion to ET-I8-O-CH3 ( Figure 3). All three inhibitors caused a loss of cell viability that was observed between 24 and 48 h.
- One aspect of the present invention is the demonstration that inhibition of CoA-IT has a role in apoptosis, and that inhibitors of CoA-IT, such as ET-I8-O-CH3 , 2-[2-[3-(4- chloro-3 -trifluoromethylphenyl) ureido] -4-trifluoromethyl phenoxy]-4,5- dichlorobenzene sulfonic acid and diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol- l-yl)heptane-phosphonate all caused apoptosis of HL-60 cells.
- inhibitors of CoA-IT such as ET-I8-O-CH3 , 2-[2-[3-(4- chloro-3 -trifluoromethylphenyl) ureido] -4-trifluoromethyl phenoxy]-4,5- dichlorobenzene sulfonic acid and diethyl 7-
- the enzyme CoA-IT orchestrates the movement of arachidonate into these phosphoiipids (Chilton et al, Biochemistry 34: 5403-5410 (1995)).
- CoA-IT inhibitors In addition to the loss from phosphatidyl- ethanolamine, CoA-IT inhibitors also blocked the incorporation of arachidonate into 1- ether-linked phosphatidylcholine . It has long been recognized that many 'cancer' cells contain high levels of 1 -ether- linked phosphoiipids and in particular 1 -alkenyl phosphatidylethanolamine (Snyder et al, Can. Res. 28: 972-978 (1968); and Snyder et al, Can. Res. 29: 251-257 (1969)). Moreover, Chabot et al. (Cancer Res.
- the normal path for inco ⁇ oration of arachidonate into 1 -ether-linked phosphoiipids is for arachidonate acid to be converted to arachidonate-CoA, to be then inco ⁇ orated into 1-acyl-linked phosphoiipids, such as l-acyl-2-arachidonate-phosphocholine.
- the enzyme CoA-IT then moves the arachidonate portion from the 1-acyl-linked phospholipid into 1 -ether-linked phosphoiipids.
- These 1 -ether-linked phosphoiipids are high in cancer cells.
- CoA-IT inhibitors block the movement of arachidonate into these 1 -ether-linked phosphoiipids, depriving cancers cells of a key component for their survival.
- inhibition of CoA-IT induces apoptosis of cancer cells, thus dramatically influencing their growth and proliferation.
- the data support the discovery, detailed herein, that inhibition of CoA-IT activity results in a decrease in cell growth and proliferation, in induction of apoptosis, with therapeutic utility in proliferative and cancerous disorders.
- This invention therefore provides a method, CoA-IT inhibition, for treating proliferative and cancerous disorders.
- alkyl lysophospholipid As used herein, the terms “alkyl lysophospholipid” (ALP), "alkyl lysophospholipid analog” and “ether-linked phospholipid and analogs thereof are well known terms to those of skill in the art and need no additional definitions. Generally these terms will encompass compounds that are ether linked phosphoiipids with alkyl chains in the sn- 1 position of the glycerol backbone.
- These compounds may be derivatives of l-O-alkyl-2-O-methyl-rac-glycero-3-phosphocholine, derivatives of l-O- hexadecyl-2-acetal-sn-glycero-3-phosphocholine (PAF), derivatives of ester- lysophospholipid (2-PLC), or derivatives of lysophophatidylcholine (2-LPC).
- PAF l-O-alkyl-2-O-methyl-rac-glycero-3-phosphocholine
- PLC ester- lysophospholipid
- 2-LPC lysophophatidylcholine
- Ether- lysophospholipids are also referred to as alkyllysoPC's, or ALPs
- alkylphosphocholines are also referred to as APCs
- HPC hexadecyl phosphocholine
- Suitable compounds encompassed by this term include but are not limited to, those described in Schick et al., Lipids, 22 (11) 904-910 (1987); such as those described in Morris- Natschke et al., J. Med. Chem., 29 (10) 2114-2117 (1986); Goto et al., Anticancer Research, 14:357362 (1994); Langen et al., Anticancer Research, 12:2109-2112 (1992); Volger et al., Lipids, 28(6) 511-516 (1993); Workman et al., Biochem.
- l-[3H]alkyl-2-lyso-GPC (30-60 Ci mmol) was purchased from New England Nuclear (Boston, MA). Common laboratory chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). l-alkyl-2-lyso-GPC was purchased from Biomol (Plymouth Meeting, PA). Silica gel G plates were from Analtech Inc. (Newark, DE). Essentially fatty acid-free bovine serum albumin was obtained from Calbiochem (San Diego, CA). Compounds ET-I8-O-CH3 was obtained from Biomol and was made as a 100 mM stock in
- Indomethacin was obtained from Sigma Chemicals.
- Arachidonyl- trifluoromethyl ketone was purchased from Cayman Chemicals, (Ann Arbor, MI). These compounds were made as stocks (5-100 mM) in dimethylsulfoxide (DMSO) and diluted in DMSO to provide final concentrations, with DMSO concentrations ranging from 0.1-1%.
- TNF (Sigma) was made as stock in distiller water and diluted to provide the desired concentrations.
- HL-60 cells were obtained from American Type Culture Collection and grown in RPMI- 1640 media supplemented with 10% fetal bovine serum at 37°, 5% CO2. Cells were seeded in T-flasks at 0.03 to 0.08 x 10 ⁇ cells / ml and used for experiments at 0.5 to 0.6 x l ⁇ 6 cells / ml. The cell concentration at the time of drug exposure was found to be important parameter (Fujiwara et al, 1994). Proliferation and apoptosis
- the functional status of cells was measured in three ways. First cell viability was assessed by the ability of the cells to exclude trypan blue stain as shown in Figure 3.
- a second, more sensitive and quantitative method was to measure DNA synthesis, using the inco ⁇ oration of [ ⁇ HJthymidine into newly-formed DNA as the index of synthesis.
- HL-60 cells were treated with various concentrations of compounds or vehicle and kept in cell culture for different lengths of time (1 to 3 days). Cells were then given a pulse of [- ⁇ HJthymidine (1 ⁇ Ci) then removed from culture 24 hours later, washed 2X with PBS and the treated with 0.2 N NaOH for 30 min followed by addition of 15% trichloroacetic acid for 2 hrs. The total sample from each well was filtered through GF/C Watman glass microfilters under vaccum and washed 3X with 5% trichloroacetic acid. The inco ⁇ oration of [*-*H]thymidine into DNA bound to the filter was quantatied using liquid scintillation spectroscopy; see Figure 4 herein.
- the final method determines not only the amount of cell death, but also provides insight into mechanism.
- cellular DNA is broken down into oligo-nucleosomal fragments which can be discerned on gels (Kerr et al, Cancer 73: 2013-2026, (1994)).
- Cells were treated for various times (3 - 24 hours) with different concentrations of compounds or vehicle.
- the washed cells were lysed by resuspending them in 200 ⁇ L of cold, sterile detergent buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.2% Triton X-l 00) and incubated on ice 30 min.
- RNA and RNA were enzymatically degraded by incubation with 75 ⁇ g / mL RNAse A for 1 hour at 37° , then 200 ⁇ g/mL Proteinase K and 0.5% SDS (final) for 1 hour at 37°.
- An internal standard of DNA was added during the cell lysis and its recovery used as a confirmation of efficient extraction of cellular DNA fragments.
- the samples were extracted twice with an equal volume of cold, buffer saturated phenol, once with phenol / chloroform / isoamyl alcohol (25:24:1, v/v), and once with chloroform. NaCl (300 mM final) and cold ethanol were added, the solution was vortexed and let stand overnight.
- CoA-IT activity was measured as described previously (Winkler et al, Biophys. Acta Lipids Lipid Metab. 1081: 339-346, (1991)) in a total volume of 100 ⁇ l.
- Microsomes (5-20 ⁇ g protein) from a 100,000 x g, 60 min centrifugation (Winkler et al, supra) were diluted in PBS with 1 mM EGTA to the desired protein concentration. The reaction was initiated by addition of l-[ ⁇ H]alkyl-2-lyso-GPC (0.1 ⁇ Ci/tube) and 1 ⁇ M final cold l-alkyl-2-lyso-GPC in assay buffer with 0.25 mg/ml fatty acid-poor bovine serum albumin. The reaction was run for 10 min at 37°. The reaction was stopped, the lipids extracted (Bligh and Dyer, Can. J. Biochem. Physiol.
- ET-I8-O-CH3 The effects of ET-I8-O-CH3 on the kinetics of the CoA-IT reaction were examined.
- Various concentrations of ET-I8-O-CH3 (0-15 ⁇ M) were mixed with variable concentrations of substrate l-alkyl-2-lyso-GPC (0.01-3 ⁇ M).
- U937 microsomes containing CoA-IT activity were added and the reaction allowed to proceed for 3 minutes at 37°.
- the amount of product formed was determined as described above and was not more than 5% of added substrate at any concentration. Analysis of the results was performed using the method of Cleland,W., Methods Enzymol. 63: 103-138, (1979); see Figure 2 herein.
- HL-60 cells were exposed to compounds or vehicle and incubated for 48 hrs. At that time, incubation was terminated by extraction (Bligh and Dyer, Can. J. Biochem. Physiol. 37: 911-917 (1959)), the phospholipid classes in the organic phase were separated and collected by normal phase HPLC (Chilton, Methods Enzymol. 187: 157- 166 (1990)).
- the phosphoiipids were converted into diradylglycerols by addition of 20- 80 units of Bacillus cereus phospholipase C (Sigma Type XIII) in 100 mM Tris HCl buffer (pH 7.4) for 2.5 -6 hr, then converted into l,2-diradyl-3-acetylglycerols by incubation with acetic anhydride and pyridine (Chilton, Methods Enzymol. 187: 157- 166 (1990)).
- the phospholipid subclasses were separated by TLC in benzene / hexane / ethyl ether (50:45:4, v/v).
- the content of arachidonate in the phospholipid subclasses was determined after base hydrosysis, performed by using 2 M potassium hydroxide in 75% ethanol (30 min, 60°C). The reaction was stopped by addition of an equal amount of water and the reaction mixture was adjusted to pH 3 with HCl. Free fatty acids were extracted with ethyl ether, solvents removed under nitrogen and the free fatty acids converted to pentafluorobenzylesters and analyzed by GC/MS (Hubbard et al., Prostaglandins 22: 349-355 (1986)). Octadeuterioarachidonic acid was used as an internal standard and mole quantities determined using a standard curved obtained using known quantities of arachidonic acid; see Figure 6 herein. Protein analysis
- Protein concentrations were determined using the method of Bradford. M., Anal. Biochem. 72: 248-254, (1976), with reagents purchased from Bio-Rad (Hercules, CA).
- the present invention demonstrates that inhibition of CoA-IT by diverse, structurally unrelated compounds can produce an apoptotic response in cancer cells, taken directly from human patients.
- Leukemic cells from these patients were treated with inhibitors of CoA-IT and proliferation measured by monitoring the inco ⁇ oration of [3H]thymidine into newly synthesized DNA.
- two structurally different inhibitors of CoA-IT activity inhibited proliferation of human cancer cells.
- inco ⁇ oration of [3H]thymidine by chronic myelogenous leukemic cells is shown following incubation with the noted inhibitors for 20 hours.
- Leukemic cells from a human patient were incubated with vehicle (DMSO), diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro- imidazol-l-yl)heptane-phosphonate (Compound III) or 2-[2-[3-(4-Chloro-3- trifluoromethylphenyl) ureido] -4-trifluoromethyl phenoxy]-4,5-dichlorobenzene sulfonic acid (Compound I) at the indicated concentrations. After 20 hours of treatment, the inco ⁇ oration of [3H]thymidine into DNA was determined as described in the Methods Section herein.
- vehicle DMSO
- Compound I 2-[2-[3-(4-Chloro-3- trifluoromethylpheny
- CoA-IT inhibitors cells were examined for the presence of DNA fragments, a hallmark of apoptosis. This was accomplished by labeling strand breads in the DNA with fluorescein dTUP with terminal transferase. Fluorecent analysis of DNA fragmentation, was performed for human leukemic cells treated with vehicle (DMSO) or diethyl 7- (3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-l-yl)heptane-phosphonate (Compound III) (25 ⁇ M) for 24 hours. The cells were stained for DNA strand breaks using a kit from Boehringer Mannheim (Cat. No 1684795) according to the manufacture's instructions.
- DMSO vehicle
- Compound III diethyl 7- (3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-l-yl)heptane-phosphonate
- the compounds of the present invention will generally be administered in a standard pharmaceutical composition obtained by admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsule, ovules or lozenges either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents.
- They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously.
- parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- the choice of form for administration as well as effective dosages will vary depending, inter alia, on the condition being treated. The choice of mode of administration and dosage is within the skill of the art.
- the compounds of the present invention can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
- a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
- suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- a suitable pharmaceutical carrier(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- the composition is in unit dose form such as a tablet or capsule.
- Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
- a typical suppository formulation comprises a compound or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- each dosage unit for oral administration contains from about 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of the compound, or a pharmaceutically acceptable salt thereof calculated as the free base.
- the pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen.
- a daily dosage regimen for an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound, or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to
- Disease states which could benefit from the inhibition of cell proliferation include, but are not limited to, rheumatoid arthritis, psoriasis, atherosclerosis, and cancers such as leukemia or solid tumors.
- the sodium salt of 2-[2-[3,5-Bis (trifluoromethyl)phenyl- sulfonamido]-4-trifluoromethylphenoxy]benzoic acid may also be prepared.
- Ethyl 6-( 1.4.5-triphenylimidazol-2-oxy)hexanoate A mixture of ethyl-6- bromohexanoate (13.38g), 1,4,5-triphenylimidazole (6.24g), potassium carbonate (13.82g) and butan-2-one (250ml) was stirred under nitrogen at reflux for 24 hours. The mixrture was filtered and the filtrate was evaporated. The residue was chromatographed on silica gel eluted with 10% ethyl acetate to give ethyl 6-(l,4,5-triphenylimidazol-2-one-
- the compound may also be synthesized in accordance with the procedures indicated in DE 3,228, 271 Al whose disclosure is inco ⁇ orated herein by reference in its entirety.
- EXAMPLE 6 5-( 1 AS-Triphenylimidazol- ⁇ -one-S-yllvalerate a) Ethyl 5-(l,4,5-triphenylimidazol-2-yloxy)valerate l,4,5-Triphenylimidazol-2-one was treated with ethyl 5-bromovalerate and potassium carbonate in butanone to give after chromatographic work-up ethyl 5-( 1,4,5- triphenylimidazol-2-yloxy)valerate, m.p.
- 3-phosphocholine 5-lipoxygenase
- PLA2 phospholipase A2
- PBS phosphate buffered saline
- TLC thin layer chromatography
- TNF tumor necrosis factor ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9507752A JPH11511130A (ja) | 1995-07-25 | 1996-07-24 | CoA−非依存性トランスアシラーゼの阻害およびアポトーシス |
EP96925501A EP0841910A4 (fr) | 1995-07-25 | 1996-07-24 | INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US223995P | 1995-07-25 | 1995-07-25 | |
US60/002,239 | 1995-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997004765A1 true WO1997004765A1 (fr) | 1997-02-13 |
Family
ID=21699854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/012257 WO1997004765A1 (fr) | 1995-07-25 | 1996-07-24 | INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0841910A4 (fr) |
JP (1) | JPH11511130A (fr) |
WO (1) | WO1997004765A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001392A1 (fr) * | 1998-07-01 | 2000-01-13 | Medmark Pharma Gmbh | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) pour traiter les cancers du sein humains |
WO2000051684A3 (fr) * | 1999-03-03 | 2001-01-04 | Scarista Ltd | Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes |
WO2008074572A1 (fr) * | 2006-12-20 | 2008-06-26 | Universitätsklinikum Hamburg-Eppendorf | Utilisation d'un composé de glycérol tri-substitué dans le traitement des hémopathies malignes |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5470882A (en) * | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5545669A (en) * | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4000084A1 (de) * | 1990-01-03 | 1991-07-04 | Medmark Pharma Gmbh | Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts) |
GB9019839D0 (en) * | 1990-09-11 | 1990-10-24 | Smith Kline French Lab | Compounds |
WO1993016674A1 (fr) * | 1992-02-11 | 1993-09-02 | Smithkline Beecham Corporation | INHIBITEURS DE LA CoA-IT ET DU PAF |
-
1996
- 1996-07-24 EP EP96925501A patent/EP0841910A4/fr not_active Withdrawn
- 1996-07-24 WO PCT/US1996/012257 patent/WO1997004765A1/fr not_active Application Discontinuation
- 1996-07-24 JP JP9507752A patent/JPH11511130A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5470882A (en) * | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5545669A (en) * | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
Non-Patent Citations (1)
Title |
---|
See also references of EP0841910A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001392A1 (fr) * | 1998-07-01 | 2000-01-13 | Medmark Pharma Gmbh | 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) pour traiter les cancers du sein humains |
WO2000051684A3 (fr) * | 1999-03-03 | 2001-01-04 | Scarista Ltd | Regulateurs de transacylase independante de la coenzyme a comme medicaments psychotropes |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
WO2008074572A1 (fr) * | 2006-12-20 | 2008-06-26 | Universitätsklinikum Hamburg-Eppendorf | Utilisation d'un composé de glycérol tri-substitué dans le traitement des hémopathies malignes |
RU2474427C2 (ru) * | 2006-12-20 | 2013-02-10 | Универзитетсклиникум Хамбург-Эппендорф | Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей |
US20130266591A1 (en) * | 2006-12-20 | 2013-10-10 | Alphaptose Gmbh | Use of tri-substituted glycerol compounds for the treatment of hematological malignancies |
Also Published As
Publication number | Publication date |
---|---|
JPH11511130A (ja) | 1999-09-28 |
EP0841910A1 (fr) | 1998-05-20 |
EP0841910A4 (fr) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Snyder et al. | Pharmacology of LY315920/S-5920,[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1 H-indol-4-yl] oxy] acetate, a Potent and Selective Secretory Phospholipase A2Inhibitor: A New Class of Anti-Inflammatory Drugs, SPI | |
Park et al. | Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation | |
Kramer et al. | p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets: evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2 | |
Insull Jr et al. | Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia | |
US5981592A (en) | Method and composition for treating cystic fibrosis | |
Conley et al. | Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics | |
US5968963A (en) | PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption | |
MXPA02007603A (es) | Usos terapeuticos de mediadores ppar. | |
KR20020010581A (ko) | 핵수용체 ppar의 신규한 리간드 | |
CZ286460B6 (en) | Medicament for prophylaxis and treating cancer of colon | |
WO1996040109A1 (fr) | Procedes d'inhibition de l'activite de phosphatase, et de traitement de pathologies associees a l'aide de naphtopyrones et de leurs derives | |
WO1994026260A1 (fr) | PROCEDES ET COMPOSES INHIBANT LES TROUBLES DE LA PROLIFERATION CELLULAIRE CARACTERISES PAR L'ACTIVITE ANORMALE D'$i(abl) | |
Winkler et al. | Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells. | |
WO1997004765A1 (fr) | INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE | |
EP1642575A1 (fr) | Utilisation de r-ains pour la prévention de la maladie d'alzheimer | |
US20160058777A1 (en) | Identification and treatment of cancer subsets | |
Stolfi et al. | Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase | |
EP3866786A1 (fr) | Compositions et procédés de suppression et/ou de traitement de maladies métaboliques et/ou d'une affection clinique associée | |
Bobola et al. | Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin | |
US20190255079A1 (en) | Compositions and methods useful for treating diseases characterized by insufficient pantothenate kinase activity | |
Peerce et al. | Inhibition of human intestinal brush border membrane vesicle Na+-dependent phosphate uptake by phosphophloretin derivatives | |
Stathopoulos et al. | Influence of 5-fluorouracil on serum lipids | |
JP6898249B2 (ja) | 心臓血管障害の治療のための方法 | |
Prestwich et al. | In situ detection of phospholipid and phosphoinositide metabolism | |
JP2004018489A (ja) | Acat−1阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 507752 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996925501 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996925501 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996925501 Country of ref document: EP |